Hepatocellular Carcinoma: Future Role of Immunotherapy – OncLive
OncLive |
Hepatocellular Carcinoma: Future Role of Immunotherapy
OncLive Ghassan Abou-Alfa, MD: While we're getting all those great results from checkpoint inhibitors, as we just discussed, you already have nivolumab onboard, you have pembrolizumab onboard, and you have durvalumab and tremelimumab in combination onboard … |
